Associated Papers
Complete response to capmatinib in a patient with metastatic lung adenocarcinoma harboring CD47-MET fusion: a case report.
Alves de Souza G et al.
The Oncologist, 2024
Somatic mutation detection and KRAS amplification in testicular germ cell tumors.
Cabral ERM et al.
Frontiers in Oncology, 2023
37007070 (PubMed )
Supplement: DataSheet_1.zip › Table_S2.XLSX › Planilha1
Liquid biopsy for patients with IBD-associated neoplasia.
Kinugasa H et al.
Bmc Cancer, 2020
Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial.
Fernández-Mateos J et al.
Scientific Reports, 2020
33024167 (PubMed )
Supplement: 41598_2020_72927_MOESM2_ESM.xlsx › Sheet1
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Rotow JK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients.
Deng Q et al.
Heliyon, 2018
30603682 (PubMed )
Supplement: mmc2.xlsx › Raw_reads_info
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
30053901 (PubMed )
Supplement: 13073_2018_564_MOESM2_ESM.xlsx › 17
FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.
Shi E et al.
Journal of Translational Medicine, 2016
27974047 (PubMed )
Supplement: 12967_2016_1075_MOESM2_ESM.xlsx › Table_S6
Select a paper to view details